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Outpatient Antibiotic Therapy
for Osteomyelitis
To the Editor.\p=m-\TheMarch 28, 1986,
issue of JAMA contained an article
offering an economic analysis of out-
patient therapy for osteomyelitis.1 This
article is now being distributed by
representatives of the Smith Klein &
Frenchpharmaceutical company for the
purpose of encouraging the use of the
cephalosporin antibiotic cefonicid (Mon-
ocid) in this setting. In their introduc-
tion, the authors justify their analysis
by noting that "a new. . . cephalo-
sporin antibiotic, cefonicid sodium, has
been shown to be effective in treating
osteomyelitis in the outpatient setting."
This statement is supported by refer-
ence to a clinical trial published in a
supplement to Reviews of Infectious
Diseases underwritten by Smith Klein
& French.2 This clinical trial examined
(in an uncontrolled fashion) cefonicid
therapy for osteomyelitis in 15 patients,
12 of whom completed therapy. The
investigators in this clinical trial appro-
priately noted the limitations of their
study: small numbers, no comparison
group, lack of randomization, and infec-
tion involving mostly small bones. The
authors stated that their data were
preliminary and "should serve only as a
stimulus for larger and longer studies of
a similar nature."
There is no question that there is a
need for less costly treatment strate¬
gies that involve outpatient intravenous
therapy, use of long-acting drugs, and
oral therapy. However, trials con¬
ducted according to rigorous clinical,
epidemiologic, and statistical principles
must form the basis for benefit-cost
analyses.34 Cefonicid has yet to be
shown to be as effective or safe as stan¬
dard therapy for the treatment of acute
osteomyelitis.
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In Reply.\p=m-\Wesympathize with Drs
Cohen and Weber's concern that physi-
cians may rely inappropriately on a
single scientific report in changing their
practices. However, they may have
misinterpreted the message of our
report on potential savings from out-
patient treatment of osteomyelitis. We
presented the use of cefonicid as an
example of a drug with which "early-
discharge therapy. . . may be en-
hanced." Based on the report by Kunkel
and Iannini,1 aswellas the submission of
data for the drug's approval, we came to
the same conclusion as the Food and
Drug Administration\p=m-\thatcefonicid is
an appropriate drug for treatment of
many cases of osteomyelitis. Our
economic analysis assumed that drug
therapywould be started in the hospital
and clinical response demonstrated
before discharge for outpatient anti-
biotic therapy. Others have reached
similar conclusions, including the au-
thors of a comprehensive review of
cefonicid,2 who wrote that "patients
who require prolonged antibiotic thera-
py, such as those with osteomyelitis
being treated after a relatively short
inpatient course, could benefit from the
once daily dose given of cefonicid."
We agree that more trials of the long-
term safety and efficacy of outpatient
antibiotic treatment of serious infec¬
tions are needed. We would add that
these clinical trials should be comple¬
mented by rigorous studies of the treat¬
ment's efficiency in order to measure
financial savings as carefully as clinical
benefit.
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Polio Vaccination
To the Editor.\p=m-\Wewere pleased to see
the careful analysis of vaccine-associat-
ed paralytic poliomyelitis by Nkowane
et al.1
One important point concerns the
estimate of the true risk of vaccine-
associated poliomyelitis in susceptible
individuals.2-4This is ofmore than theo-
retical interest: in view of the changing
epidemiologic situation in developed
and developing countries, one has to
assume that more and more children
being vaccinated for the first time will
be fully susceptible to all three polio-
virus types. Thus, the rate of vaccine-
associated poliomyelitis may be in-
creasing.
Needless to say, this does not call into
question the extraordinary blessings of
oral poliomyelitis vaccination, par-
ticularly in developing countries. But,
whenever feasible, consideration
should be given to a combined vaccina-
tion strategy using inactivated polio-
myelitis vaccine for the first polio vacci-
nations in early infancy, together with
diphtheria, tetanus, and pertussis vac-
cination. This protocol carries the addi-
tional advantage of avoiding the possi-
ble risk of increasing the incidence of
paralytic poliomyelitis by the simulta¬
neous administration of intramuscular
injections and of oral polio vaccine.M
Another lesson to be learned from the
contact cases (in these days involving
even grandparents) is that vaccination
of all household members should be
urged, or that at least strict hygienic
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